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Abstract 
In established multiple sclerosis (MS), tissue abnormality - as assessed using 
magnetisation transfer ratio (MTR) – increases close to the lateral ventricles. 
We aimed to determine whether or not i) these changes are present from the 
earliest clinical stages of MS; ii) they occur independent of white matter 
lesions; and iii) they are associated with subsequent conversion to clinically 
definite MS and disability. 
 
Seventy-one people had MRI scanning a median of 4.6 months after a 
clinically isolated optic neuritis (ON, 49 females, mean age 33.5 years) and 
were followed up clinically two and five years later. Thirty-seven healthy 
controls (25 females, mean age 34.4 years) were also scanned. In normal-
appearing white matter (NAWM), MTR gradients were measured 1-5mm and 
6-10mm from the lateral ventricles. 
 
In controls, MTR was highest adjacent to the ventricles and decreased with 
distance from them; in ON, NAWM MTR was lowest adjacent to the ventricles, 
increased over the first 5mm, and then paralleled control values. The MTR 
gradient over 1-5mm differed significantly between the ON and control groups 
(+0.059 percentage units/mm (pu/mm) vs -0.033 pu/mm, p=0.010), and was 
significantly steeper in those developing clinically definite MS within two years 
compared to those who did not (0.132 pu/mm vs 0.016 pu/mm, p=0.020). In 
multivariate binary logistic regression the MTR gradient was independently 
associated with the development of clinically definite MS within two years 
(MTR gradient odds ratio (OR) 61.708, p=0.023; presence of T2 lesions OR 
8.500, p=0.071). At five years, lesional measures overtook MTR gradients as 
significant predictors of conversion to MS. The MTR gradient was not 
significantly affected by the presence of brain lesions (T2 lesions (p=0.918), 
periventricular T2 lesions (p=0.580) or gadolinium-enhancing T1 lesions 
(p=0.724)). The MTR gradient also correlated with Expanded Disability Status 
Scale (EDSS) score five years later (Spearman r=0.313, p=0.027). 
 
An abnormal periventricular MTR gradient occurs early in MS, is clinically 
relevant, and may arise from one or more mechanisms that are at least partly 
independent of lesion formation. 
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Abbreviations 
ANOVA = analysis of variance; BPF = brain parenchymal fraction; CDMS = 
clinically definite multiple sclerosis; CIS = clinically isolated syndrome; GM = 
grey matter; MTR = magnetisation transfer ratio; NAWM = normal-appearing 
white matter; ON = optic neuritis; PD = proton density; RRMS = relapsing 
remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis 
 
  
Introduction 
In people with established MS, it has recently been shown that magnetisation 
transfer ratio (MTR) is increasingly abnormal in NAWM and WM lesions close 
to the lateral ventricles (Liu et al., 2015). Several mechanisms may be 
responsible for this periventricular MTR gradient, and it is unclear whether the 
underlying process differs from those leading to WM lesion formation. It is 
also not known if such a periventricular predilection for non-lesional WM 
pathology occurs early in MS or is associated with subsequent disease 
activity. An early, clinically-relevant change that is independent of lesions 
might represent an early treatment target. 
 
About 80% of people with MS initially present with a clinically isolated 
syndrome (CIS) such as optic neuritis (ON). About two-thirds of people with a 
CIS have asymptomatic brain white matter (WM) lesions visible on MRI, and 
these are associated with a substantially greater risk of subsequently 
developing clinically definite (CD) MS (80% compared with 20% for those who 
do not have such lesions (Fisniku et al., 2008)). However, WM lesions are not 
the only abnormality found early in people with MS: GM lesions are also seen 
(Calabrese et al., 2007; Nielsen et al., 2013), and normal-appearing (NA) WM 
and GM are both abnormal when assessed using quantitative MRI measures 
(for example (Fernando et al., 2005; Gallo et al., 2005; Rocca et al., 2008; 
Henry et al., 2009). 
 
By looking for an abnormal periventricular MTR gradient in people who have 
recently had a CIS, we would be able to establish if it is seen from the earliest 
clinical stages of MS and, given that people usually have very few WM lesions 
immediately after a CIS, determine if it is closely associated with WM lesions. 
Using previously acquired MTR data from a longitudinal study of people with a 
recent CIS, we aimed to (1) look for gradients in NAWM abnormalities around 
the lateral ventricles and, if present, to determine (2) whether or not they were 
associated with WM lesions, or (3) were associated with the subsequent risk 
of developing MS and disability. 
 
 
Materials and methods 
Participants 
From a prospectively recruited CIS cohort (Fernando et al., 2005) we included 
data from 81 people who had presented with a clinically isolated ON, who had 
no previous history of neurological symptoms, were aged between 16 and 50 
years at symptom onset, had 3D fast spoiled gradient echo (FSPGR) as part 
of their baseline MRI assessments and MTR three months later. Participants 
were recruited from Moorfields Eye Hospital (London) by a single experienced 
neuro-ophthalmologist. They were evaluated clinically and with MRI a median 
of 1.4 (range 0.1-3.5) months after ON onset (‘baseline’) and underwent a 
further scan (including magnetization transfer imaging) on the same scanner 
three months later (median 4.6; mean 4.8; range 2.0-7.5 months after ON 
onset); patients were followed up clinically two and five years later (Brownlee 
et al., 2015) and had EDSS and paced serial addition test (PASAT, 3 second 
intervals (Cutter et al., 1999)) scores assessed at five years. This work 
therefore describes cross-sectional MTR data (collected 4.6 months after 
symptom onset) with clinical data at 4.6 months plus two and five years after 
symptom onset. We also studied a group of 39 healthy controls with no known 
neurological disorder or clinical follow up. Demographic and clinical data are 
reported in Table 1.  
 
All participants gave written informed consent and the study was approved by 
our local institutional ethics committees. 
 
Clinical assessments 
MS was diagnosed on the basis of further relapses (clinically definite multiple 
sclerosis (CDMS, (Poser et al., 1983) and using the 2010 McDonald criteria 
(Polman et al., 2011).  
 
Magnetic resonance imaging 
All magnetic resonance studies were performed on a 1.5 Tesla (T) GE Signa 
Echospeed scanner (General Electric Medical Systems, Milwaukee, WI). The 
following sequences were acquired: (i) an FSPGR scan of the whole brain 
(124x1.5mm slices; matrix, 256x160, interpolated to a final in-plane resolution 
of 1.1mm, TR= 10.9 ms, TE= 4.2 ms, TI= 450 ms) for volumetric measures; 
(ii) dual echo proton-density (PD)/T2 scans of the whole brain (46x3 mm 
contiguous axial-oblique slices parallel to the anterior/posterior commissural 
line, matrix 256x256, FOV 24x18 cm, TR=3200 ms, TE=15/90 ms), for the 
evaluation of WM lesions; (iii) T1-weighted pre- and post-gadolinium (0.1 
mmol/kg body weight) spin echo sequences of the brain (46x3 mm contiguous 
axial-oblique slices parallel to the anterior/posterior commissural line, matrix 
256x256, FOV 24x18 cm, TR=600 ms, TE=17 ms) to evaluate the presence 
of pathologically enhancing lesions; and (iv) MTR data using a dual-echo, 
spin-echo sequence of the whole brain (28x5mm contiguous, axial-oblique 
slices parallel to the anterior/posterior commissural line with an interleaved 
sequence described by Barker (TR=1720 ms, TE=30/80ms, number of 
excitations 0.75, matrix 256x128, FOV 24x24cm, MT-weighted by the 
application of a pre-saturation pulse (Hamming apodized 3 lobe sinc pulse, 
duration 64ms, flip angle 1430°, and a peak amplitude of 14.6 μT giving a 
normal bandwidth of 62.5 Hz, applied 1kHz from the water resonance (Barker 
et al., 1996))). MTR maps were calculated on a voxel-by-voxel basis using the 
short echo data because of its higher signal to noise compared to the longer 
echo data. PD and T2-weighted images are included in this sequence, 
intrinsically registered to the MT data, and were used to facilitate registrations 
to native MT space as described below. The FSPGR scan was acquired at 
baseline (when magnetisation transfer imaging was not performed); all other 
scans and lesion counts used for this analysis were acquired three months 
later (when the FSPGR was not repeated (Fernando et al., 2005)). 
 
Image analysis 
MTR map calculation 
For each participant, MTR maps were calculated using the following equation: 
MTR (in percentage units (pu)) = ((MTRoff – MTRon) / MToff.) x 100). The 
interleaved nature of the MTR sequence used meant that co-registration of 
MTon and MToff data was not required. MTR values were extracted from each 
NAWM and lesion ring using FSLstats (http://www.fmrib.ox.ac.uk/fsl/). 
 
 
Tissue segmentation  
T1-hypointensities were outlined using a semi-automated edge-finding tool 
(JIM v6.0, Xinapse systems, Aldwincle, United Kingdom) on the 3D FSPGR 
images and these masks were used to perform lesion filling on the 3D FSPGR 
scans (Chard et al., 2010; Prados et al., 2016). After lesion filling the FSPGR 
scans were segmented into grey matter (GM), WM and cerebrospinal fluid 
(CSF) probability maps using the new segmentation pipeline in Statistical 
Parametric Mapping 12 (SPM12; Wellcome Trust Centre for Neuroimaging, 
London, UK; www.fil.ion.ucl.ac.uk/). Brain parenchymal fraction (BPF) was 
calculated using SPM12-derived tissue segmentations for use as a covariate 
in the statistical models (Chard et al., 2010). 
 
Generation of NAWM masks 
WM lesions were identified on the dual echo proton-density (PD)/T2-weighted 
scans, and outlined using JIM v6.0 (Xinapse systems, Aldwincle, United 
Kingdom) by one investigator (WJB). Using NiftyReg (Modat et al., 2010; 
Modat et al., 2014) the T2-weighted image was linearly co-registered with the 
T2-weighted image embedded in the MT sequence, thus aligning the WM 
lesion masks with the MTR maps. NiftyReg implements a symmetric and inverse-
consistent registration ensuring that the results are unbiased towards the 
directionality of the registration process because the forward and backward 
transformations are optimised concurrently in an inverse-consistent manner. The 
symmetric full affine approach (Modat et al., 2014) with 12 degrees of freedom is 
based on the asymmetric block-matching approach (Ourselin et al., 2001). 
 
The PD and T2 images embedded in the MT sequence were used to generate 
a pseudo-T1 image, by subtracting the PD scans from the T2 images 
(Hickman et al., 2002). For each participant, the 3D FSPGR scan was then 
linearly co-registered to the pseudo-T1 using NiftyReg (Modat et al., 2014) 
and the transformation applied to the GM, WM and CSF tissue segmentation 
maps. In MTR space the GM, WM and CSF maps were binarised using a 
probabilistic threshold of > 90% (Samson et al., 2014). In MTR space, WM 
lesion masks were dilated by two voxels (to account for perilesional MTR 
abnormalities (Vrenken et al., 2006)), and the dilated lesion masks were 
subtracted from the thresholded WM tissue probability maps to produce 
NAWM masks. 
 
Segmentation of NAWM into concentric periventricular rings 
Given the voxel size of MT images (1x1x5 mm), to reduce the potential for 
partial volume effects between CSF and WM all analyses were limited to two 
axial slices orthogonal to the wall of the lateral ventricles, i.e. a slice 
immediately above the insula, and the slice immediately below this. To 
consistently identify these slices in all participants, a position marker was 
placed in the lateral ventricles just superior to the insula on a MNI152 brain 
template (Grabner et al., 2006). The MNI152 brain template was registered to 
each participant’s native MTR space with a non-linear transformation as 
previously described (Muhlert et al., 2013) using NiftyReg (Modat et al., 
2010). The position of the marker was checked and corrected as needed by 
one investigator (JWLB) and then the two axial slices were selected relative to 
this template marker. 
 
To identify the lateral ventricles we used a previously described approach (Liu 
et al., 2015). Briefly, a mask of the lateral ventricles was created in MNI152 
space using the Wake Forest University School of Medicine PickAtlas toolbox 
(Maldjian et al., 2003) and then registered to each participant’s MTR native 
space using the previously computed transformation. The lateral ventricle 
mask was then intersected with each participant's CSF mask on the two 
previously selected axial slices. These masks were checked and manually 
edited by one investigator (JWLB) to ensure anatomical accuracy, and then 
sequentially dilated in the axial plane by 1 voxel (1mm) using DilM (part of 
FSL software package (http://www.fmrib.ox.ac.uk/fsl/) producing concentric 
rings around the lateral ventricles (Fig. 1). The first two rings were discarded 
to limit partial volume effects from CSF as each of these contained CSF in 
over half of participants (first ring 117/120 participants; second ring 63/120). 
As per previous work (Liu et al., 2015), WM lesional MTR and the percentage 
of lesioned WM were computed for the next ten rings. Residual CSF was 
identified in the first of these ten rings in ten people with ON and two controls 
and so these participants were excluded, leaving 71 people with ON and 37 
healthy controls. 
 
We also recalculated the mean NAWM and GM MTR (as reported in 
(Fernando et al., 2005) for use as covariates in the statistical models. 
 
Statistical analyses 
Statistical analyses were performed using SPSS (IBM SPSS version 22 for 
Windows (SPSS, Inc., Chicago, IL, USA)). Demographic data are presented 
as mean (standard deviation) and MTR data as mean (standard error), while 
EDSS values are presented as median (range). In each participant, mean 
MTR values were calculated in the 1 mm rings in both axial slices, and then 
averaged across both slices, weighted by the number of voxels in each ring. 
After discarding the first two rings (see above), we calculated periventricular 
MTR gradients over the next 5mm closest to the ventricles (i.e. NAWM MTR 
in ring five – NAWM MTR in ring one) and deep MTR gradients over the 
subsequent 5mm (i.e. NAWM MTR in ring ten – NAWM MTR in ring six), 
dividing both by the number of intervals to give the MTR change in 
percentage units (pu) per mm. This division was consistent with previous work 
(Liu et al., 2015), and coincided with the point at which the MTR gradients in 
the ON and control groups converged (Fig. 2A).  
 
In the ON cohort, 58/71 patients were followed-up two and five years after 
their baseline MRI scan. These patients were subdivided into those who 
developed CDMS or McDonald MS within two years of their ON. We also 
examined those developing CDMS and McDonald MS within five years of 
their ON. To assess associations with gadolinium-enhancing lesions, the ON 
cohort was subdivided into those with or without enhancing lesions. To 
explore associations with WM lesions, the ON cohort was also subdivided into 
those who did or did not have asymptomatic T2 WM lesions and, in those with 
lesions, those who did or did not have periventricular lesions. Independent 
sample t-tests and analysis of variance (ANOVA) tests were used to compare 
clinical and MRI measures between groups. For the MTR gradient measures, 
the same comparisons were also performed using general linear models firstly 
correcting for BPF (to control for the possible effects of atrophy on 
periventricular MTR gradients), then correcting for mean NAWM and GM MTR 
(to ensure diffuse MTR changes were not driving MTR gradients).  Spearman 
correlation was used to explore the relationship between MTR gradients and 
both EDSS and PASAT scores. Factors predicting conversion to CDMS status 
were examined with multivariate binary logistic regression. Results were 
considered statistically significant at the p<0.05 level. 
 
 
Results 
There were no significant demographic differences between the clinically 
isolated ON group and controls (Table 1). At the three-month scan, 55/71 
(77.5%) of the optic neuritis group had WM lesions, 46/71 (64.8%) had 
periventricular lesions and 22/71 (31.0%) had gadolinium-enhancing lesions. 
Thirteen patients were lost to follow-up. After two years, 18/58 (31%) had 
experienced a further clinical relapse and so developed CDMS while 40/58 
(69%) had McDonald MS. Five years after ON, these figures had risen to 
31/58 (53.5%) and 45/58 (77.6%) respectively. 
 
Periventricular MTR gradients in ON compared with controls 
Table 2 and Fig. 2A show the mean and standard error (SE) NAWM MTR per 
ring in the ON and control groups. The mean MTR of each NAWM ring was 
lower in the ON group than in healthy controls. In controls, mean MTR was 
highest in the rings nearest the ventricles and declined with distance from 
them. In contrast, in the ON group, mean MTR was lowest in the ring nearest 
the ventricles, increased over the first 5mm and then paralleled control values. 
 
Over the first 5mm from the ventricles, we found significantly different MTR 
gradients between the ON and control groups (ON: mean +0.059 pu/mm ± 
0.028; controls mean -0.033 pu/mm ± 0.028, t=-2.62, p=0.010). This 
difference remained significant after adjustment for BPF (p=0.009). 
Conversely, the MTR gradient over the next five rings showed no significant 
difference between the groups (ON: +0.003 pu/mm ± 0.008, controls -0.009 
pu/mm ± 0.012, p=0.541). 
 Associations of periventricular MTR gradients with lesions 
In the ON group, over the first 5mm periventricular MTR gradients did not 
differ significantly between those with or without asymptomatic WM lesions 
seen on a T2-weighted scan from the same scanning session (+0.058 pu/mm 
± 0.024 vs +0.063 pu/mm ± 0.043 respectively, p=0.918). The periventricular 
MTR gradient in the ON group who did not have brain lesions showed a non-
significant trend to be higher than healthy controls (+0.063 pu/mm ± 0.043 vs 
-0.033 pu/mm ± 0.028 respectively, p=0.064), Fig. 2B. The presence of 
periventricular lesions seen on a T2-weighted scan had no significant effect 
on the periventricular gradient (0.068 pu/mm ± 0.028 (with periventricular 
lesions) vs 0.043 pu/mm ± 0.030 (without periventricular lesions), p=0.580, 
Fig. 2C). The mean gradient in those with and without gadolinium-enhancing 
lesions similarly did not differ significantly (0.067 pu/mm ± 0.040 vs 0.055 
pu/mm ± 0.025 respectively, p=0.794). 
 
Associations of periventricular MTR gradients with conversion to MS and 
disability  
Table 3 and Fig. 2D show the gradients over the first and second 5mm of 
NAWM extending from the ventricles in the ON groups who did or did not 
develop CDMS within two years. 
 
The periventricular MTR gradient in the group who developed CDMS within 
two years differed from healthy controls and the ON group who did not 
convert to CDMS within two years (Table 3; overall effect p=0.006; converters 
vs. healthy controls p=0.001, converters vs. non-converters p=0.020, non-
converters vs. healthy controls p=0.221). The periventricular MTR gradient 
also differed between those who converted to CDMS within five years and 
healthy controls, while the difference between converters and non-converters 
did not reach significance; overall effect p=0.026; converters vs. healthy 
controls p=0.007, converters vs. non-converters p=0.123, non-converters vs. 
healthy controls p=0.304). The differences between those who developed MS 
and HC remained significant when McDonald MRI criteria were used instead 
of CDMS (Table 3). The group effect on the periventricular MTR gradient did 
not materially change after including BPF in the statistical models. The group 
effect on the periventricular MTR gradient also remained significant after adjustment 
for mean NAWM MTR (p=0.014) and mean GM MTR (p=0.022). When both NAWM 
MTR and GM MTR were added, the model remained significant (p=0.021) as did 
differences in MTR gradients between converters and non-converters (p=0.037) and 
between converters and healthy controls (p=0.006). 
 
We also examined whether or not periventricular MTR gradients over 1-5mm 
had an effect on conversion to CDMS independent of the presence of lesions. 
A multivariate binary logistic regression showed that the MTR gradient over 1-
5mm was independently associated with conversion to CDMS at two years 
(MTR gradient: odds ratio (OR) 61.708 p=0.023; presence of T2 lesions OR 
8.500 p=0.071). A similar pattern was seen when the MTR gradient was 
compared to periventricular T2 lesions (MTR gradient: OR 44.100 p=0.029; 
presence of periventricular T2 lesions OR 5.84 p=0.040). However, the MTR 
gradient did not predict conversion to CDMS over five years. 
 
There was no significant difference in 6-10 mm MTR gradients between ON 
groups who did or did not develop CDMS at two or five years (p=0.124 and 
p=0.231 respectively). 
 
Unlike the periventricular MTR gradient, the mean MTR of band 1 or 5 in the 
ON group converting to CDMS within 2 years was not significantly higher than 
in those not converting to CDMS (see Supplementary Data). 
 
Associations of MTR gradient, mean NAWM MTR and mean GM MTR with 
disability.  
A correlation was found between the MTR gradient over the first 5mm and 
EDSS status five years later (Spearman r=0.313, p=0.027; EDSS measured 
in 50/58 patients at this time point). No significant correlation was found 
between inner MTR gradient and PASAT score at five years (p=0.815), 
although this was only undertaken in 31/58 patients at this time point. 
No significant correlations were found between EDSS five years later and 
mean MTR in band 1 (p=0.165) or band 5 (p=0.540), NAWM MTR (p=0.506) 
or GM MTR (p=0.109). 
 
Lesion measures 
The mean MTR of lesional voxels, like the NAWM MTR, was lowest at the 
ventricular margin and increased with distance from it (see Fig. 3). Lesion 
volumes are shown in Fig. 4.  
 
 
  
Discussion 
In a previous study in people with established RRMS and SPMS we found 
that MS effects on NAWM MTR increased close to the lateral ventricles (Liu et 
al., 2015). However, we could not determine how early in the clinical course of 
MS this abnormal periventricular MTR gradient occurred, whether or not it 
was due to a mechanism independent of WM lesion formation, or if it was 
associated with subsequent disease activity. In the present study we found 
that an abnormal periventricular MTR gradient is present within five months of 
a clinically isolated ON, is not dependent on the presence of WM lesions and 
is associated with the subsequent risk of developing MS and disability. Both 
the periventricular NAWM MTR gradient and WM lesions independently 
predicted conversion to CDMS over two years. This raises the possibility that 
lesions and NAWM periventricular abnormalities in early MS may arise from 
different but nevertheless clinically relevant pathophysiological processes. 
 
In the ON group we looked for significant differences in the periventricular 
MTR gradients between those with and without asymptomatic WM lesions, 
those with and without periventricular WM lesions, and those with and without 
gadolinium-enhancing lesions, and found none. Consistent with previous work 
(Liu et al., 2015) MTR in lesions also showed periventricular gradients similar 
to those in NAWM. Collectively, this strongly suggests that abnormal 
gradients in NAWM MTR are not dependent on the presence of WM lesions. 
In keeping with previous results (Barkhof et al., 1997) periventricular lesions 
predicted conversion to CDMS over two years, and in a multivariate logistic 
regression the MTR gradient over 1-5mm also independently predicted 
conversion to CDMS over two years. The identification of an early abnormal 
periventricular MTR gradient that is not directly related to lesion formation, but 
linked with clinical outcomes suggests that there is a pathological process 
distinct to that underlying lesion formation. 
 
The pathological basis of the abnormal periventricular MTR gradient is 
uncertain. MTR correlates with myelin and axonal density (Schmierer et al., 
2007) and may also be reduced by tissue oedema and inflammation (Dousset 
et al., 1992; Gareau et al., 2000). To the best of our knowledge, there have 
been no histopathological studies looking for a gradient of pathology in extra-
lesional periventricular WM. Several mechanisms could underlie the 
periventricular MTR changes seen, perhaps in combination, but without 
knowing the underlying pathological substrate we can only speculate which 
are responsible. 
 
Considering first factors external to the brain, CSF-mediated and ependymal 
processes may both influence MS pathology, particularly in tissues close to 
the surface. CSF from people with a CIS or MS has been found to cause 
neuronal death in vitro (for example (Alcazar et al., 2000; Vidaurre et al., 
2014)), and when sampled at the time of relapse in RRMS induces 
oligodendrocyte apoptosis (Menard et al., 1998). In addition, leucocytes can 
enter the CSF space through the choroid plexus, and in people with MS the 
concentration of the tight junction protein claudin-3 - which helps maintain the 
blood-CSF barrier integrity - is lower when compared with healthy controls 
(Kooij et al., 2014). ‘Granular ependymitis’ has been reported at post-mortem 
in some people with MS, however while it is associated with 1 in 10 
periventricular lesions it is also evident distant from lesions, and is seen in 
non-inflammatory central nervous system conditions (Adams et al., 1987). 
 
Within the brain, there are several mechanisms through which a 
periventricular pathological gradient might arise. Axons and oligodendrocytes 
are susceptible to hypoxia, and the periventricular venous watershed renders 
this region intrinsically susceptible to hypoperfusion and hypoxia (Andeweg, 
1996); periventricular hypoperfusion is significantly greater in MS than 
controls and is evident even after a CIS (Dewar et al., 2003; Varga et al., 
2009; Beggs, 2013). WM lesions nearly always form around veins, and the 
high venular density around the lateral ventricles likely accounts for WM 
lesions’ periventricular predilection (Brownell and Hughes, 1962; Adams et al., 
1987; Narayanan et al., 1997; Evangelou et al., 2000). However, we think that 
lesions themselves are unlikely to directly explain the WM periventricular MTR 
gradient, as we have excluded lesions plus a two voxel-layer NAWM 
perilesional cuff, and extending this to a four voxel-layer cuff in our previous 
work did not materially alter the results (Liu et al., 2015). A tract-mediated 
effect of lesions may also contribute to gradients: adjacent to the lateral 
ventricles run multiple WM tracts (e.g. those in the corpus callosum, and so it 
may be expected the remote effects of axonal transection in lesions (Trapp et 
al., 1998) will be more apparent in regions with high compared with low 
densities of parallel tracts. Again, we think that it is unlikely that this explains our 
present results as the periventricular MTR gradient did not significantly differ 
between those who did and those who did not have additional asymptomatic 
brain lesions, and the mean lesion load was low (~1.5 ml).  
 
Elucidating the responsible mechanism(s) may have significant implications 
for early MS treatment. For example, in established MS, neuropathological 
work has shown a cortical gradient in neuronal loss (Magliozzi et al., 2010) 
where an MTR gradient has also been identified (Samson et al., 2014). If a 
gradient in axonal loss were confirmed around the ventricles, one might infer 
that the in vivo periventricular MTR findings indicate a neurodegenerative 
process that should be targeted from the earliest clinical stages of MS. 
 
There are a few study limitations worth noting. First, we used previously 
acquired MTR data with lower resolution (1x1x5mm) than that used in our 
recent study examining periventricular gradients in established MS 
(1x1x1mm, (Liu et al., 2015) and given this, partial volume effects were a 
greater concern. To minimize these, we restricted our analysis to two axial 
slices perpendicular to the lateral ventricular wall, so avoiding oblique CSF-
WM boundaries within periventricular voxels, and through plane smoothing of 
periventricular MTR gradients (recalling that these were seen over the first 5 
mm around the ventricles, and the axial slices were 5 mm thick). Despite this, 
the first two periventricular rings still contained CSF in the majority of 
participants, and so these rings were also excluded from subsequent 
analyses. Noting that the periventricular MTR gradient seen in previous work 
was steepest close to the ventricles (Liu et al., 2015), it is likely that excluding 
these rings will have significantly reduced our sensitivity to gradients. In 10/81 
participants with ON and 2/39 healthy controls, there was still CSF in the third 
ring so these participants were also excluded from the analyses, further 
reducing the power of the study to detect periventricular gradients. While we 
were very careful to avoid partial volume effects between CSF and WM, 
partial volume between periventricular rings will tend to smooth MTR 
gradients, and so reduce sensitivity to disease effects. Similarly, restricting 
our analysis to two axial slices, while limiting the risk of MTR gradients being 
smoothed through plane, substantially reduced the volume of each ring 
studied when compared to our previous study using 1x1x1mm MTR data; this 
too is likely to have reduced sensitivity to disease effects. To allow for brain 
atrophy, which could exacerbate this further, we included BPF as a covariate 
when looking for differences in MTR gradients between clinical subgroups, 
and found no material difference in the results. To provide context with 
established MTR metrics and confirm that the difference in MTR gradient 
between converters and non-converters was not simply driven by diffuse 
tissue differences, we added NAWM and GM MTR as covariates and the 
MTR gradient remained a significant factor. 
 
By five years, about ~55% of the ON group developed CDMS, while at the 
time of their MTR scan only ~10% had done so (Table 1). The pattern of 
group differences in periventricular MTR gradient were still apparent, albeit 
with less statistical significance, following exclusion of those converting before 
the MTR scan (see Supplementary Data). As such, we think it is unlikely that 
the apparent predictive power of the periventricular MTR gradient for 
conversion to CDMS within 5 years is simply due to such a gradient being 
present in those who had already developed CDMS by the time of their MTR 
scan. Thirteen of the 71 people with ON studied at baseline did not have 
clinical follow-up. There were no significant differences in any baseline 
demographic features between those who were or were not followed up (see 
Supplementary Table 1), so we believe this is unlikely to have biased our 
results in favour of detecting differences in periventricular MTR gradients 
between groups, but it may have reduced our sensitivity to them. 
 
While we have assessed cross-sectional differences in MTR measures 
between the HC and ON groups, it would be of considerable interest to see 
how these differences evolve with time, and whether or not these changes 
relate more closely to clinical outcomes. Some longitudinal MTR data is 
available for the present cohorts (HC n = 18, ON n = 44), but the resolution of 
the 2D MTR scans (1 x 1 x 5mm) means that it is not possible to accurately 
align the same axial slices over time. When we looked for changes in 
periventricular MTR gradients over time without registering scans, we found 
no significant change over 5 years. 
 
It is well recognised that a substantial number of people with MS may have 
significant cognitive deficits (Langdon, 2011).  However, only about half 
(31/58) of those followed-up at 5 years underwent cognitive testing, of whom 
only 12 had developed clinically definite MS. Given this, it is perhaps 
unsurprising that we did not find a correlation with periventricular MTR 
gradients in this cohort, and this would perhaps be better examined in a group 
of people with progressive MS who are more likely to have cognitive 
impairment (Langdon, 2011). 
 
The parent cohort’s principal presenting CIS was ON, and for consistency we 
excluded three non-ON participants who would otherwise have been eligible 
for our study. In some cohorts, ON appears to carry a lower risk of conversion 
to CDMS when compared with other presentations (Tintore et al., 2015) and it 
would be of interest to see if periventricular gradients differ dependent on the 
type of CIS. 
 
While inner periventricular MTR gradients independently contributed to the 
prediction of conversion to CDMS and McDonald MS, there was substantial 
overlap in the range of values between groups (see Supplementary Data) and 
no clear threshold was found beyond which conversion to MS by 5 years was 
inevitable. As such measurement of periventricular MTR gradients using the 
methods employed in this study is unlikely to be useful in clinical practice. 
However, this does not negate the clinical relevance of the pathological 
processes underlying abnormal MTR gradients, which - independent of those 
leading to WM lesion formation - may be a potential target for treatments. 
 
In conclusion, our findings show that an abnormal periventricular MTR 
gradient occurs soon after a CIS and is associated with subsequent 
conversion to MS and disability. The abnormal periventricular MTR gradient 
was not significantly affected by the presence of WM lesions, and therefore 
seems likely to arise from an at least partly independent mechanism. 
Histopathological studies are warranted to elucidate the nature of these MTR 
gradients.   
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Table 1: Participant characteristics. 
 Healthy 
Controls 
People with 
optic neuritis 
N N= 37 N = 71 
Mean age, years ± SD (range) 34.4 ± 4.8 
(27-47) 
33.5 ± 6.7 (20-
48) 
female : male  25 : 12 49 : 22 
Median baseline EDSS (range) - 1 (0-3) 
Number with abnormal T2 scan 
(excluding symptomatic lesion) 
- 55 
Number with periventricular lesions - 46 
Number with Gd-enhancing lesions - 22 
Mean T2 lesion volume (ml) ± SD - 1.47 ± 3.32 
Mean brain parenchymal fraction ± 
SD 
0.84 ± 0.04 0.85 ± 0.03 
Number attaining CDMS at time of 
MTR scan 
- 8 
Number attaining McDonald MS at 
time of MTR scan 
- 33 
Number with clinical follow-up at two 
and five years 
- 58 
Number converting to CDMS within 
two years of ON (of 58 with clinical 
follow up) 
- 18 
Number converting to McDonald MS 
within two years of ON (of 58 with 
clinical follow up) 
- 40 
Number converting to CDMS within 
five years of ON (of 58 with clinical 
follow up) 
- 31 
Number converting to McDonald MS 
within five years of ON (of 58 with 
clinical follow up) 
- 45 
Median (range) EDSS score at five 
year follow-up (assessed in 50/58) 
- 1 (0-8.5) 
Median (range) PASAT score at five 
years follow-up (assessed in 31/58) 
- 46.5 (17-59) 
 
In the optic neuritis group, MTR scans were undertaken three months after 
first enrolment in the study, and so lesion measures from scans obtained at 
three months are shown. Volumetric brain scans were acquired at baseline 
but not three months. CDMS = clinically definite multiple sclerosis. EDSS = 
Expanded Disability Status Scale.  ON = optic neuritis. PASAT = paced serial 
addition test, 3 second intervals. SD = standard deviation.   
Table 2: Mean ring MTR in healthy controls and people with optic neuritis. 
Rin
g 
Mean ± SE MTR in 
pu 
Mean ± SE MTR in pu 
 Healthy 
controls  
(n=37) 
All Optic 
Neuritis 
(n=71) 
Optic Neuritis subgroups 
Convert to 
CDMS <2y  
(n=18) 
Convert to 
CDMS 2-5y  
(n=13) 
Did not 
convert to 
CDMS 
(n=27) 
1 38.364 ± 
0.138 
37.670 ± 
0.102 
p = 
0.000 
37.371 ± 
0.183  
p = 0.000 
37.831 ± 
0.180  
p = 0.062 
37.805 ± 
0.203  
p = 0.013 
2 38.334 ± 
0.113 
37.836 ± 
0.085 
p = 
0.001 
37.639 ± 
0.166 
p = 0.001 
37.773 ± 
0.205  
p = 0.020 
37.951 ± 
0.156  
p = 0.043 
3 38.254 ± 
0.095 
37.912 ± 
0.080 
p = 
0.007 
37.862 ± 
0.176  
p = ns 
37.946 ± 
0.209  
p = ns 
37.903 ± 
0.133  
p = ns 
4 38.293 ± 
0.080 
37.959 ± 
0.075 
p = 
0.003 
37.944 ± 
0.158  
p = ns 
37.942 ± 
0.190  
p = ns 
37.918 ± 
0.132  
p = ns 
5 38.232 ± 
0.080 
37.936 ± 
0.076 
p = 
0.009 
37.901 ± 
0.163  
p = ns 
37.916 ± 
0.204  
p = ns 
37.859 ± 
0.126  
p = ns 
6 38.109 ± 
0.087 
37.827± 
0.077 
p = 
0.017 
37.822 ± 
0.162 
p = ns 
37.807 ± 
0.209 
p = ns 
37.765 ± 
0.129 
p = ns 
7 38.006 ± 
0.083 
37.751 ± 
0.074 
37.751 ± 
0.166 
37.772 ± 
0.194 
37.706 ± 
0.124 
p = 
0.025 
p = ns p = ns p = ns 
8 38.024 ± 
0.084 
37.774 ± 
0.073 
p = 
0.027 
37.754 ± 
0.174 
p = ns 
37.805 ± 
0.192 
p = ns 
37.740 ± 
0.115 
p = ns 
9 38.113 ± 
0.084 
37.864 ± 
0.075 
p = 
0.030 
37.805 ± 
0.187 
p = ns 
37.942 ± 
0.192 
p = ns 
37.822 ± 
0.117 
p = ns 
10 38.187 ± 
0.085 
37.952 ± 
0.078 
p = 
0.044 
37.850 ± 
0.191 
p = ns 
38.048 ± 
0.198 
p = ns 
37.945 ± 
0.123 
p = ns 
 
Independent sample t-tests were used to compare the healthy control and 
whole optic neuritis groups; one-way ANOVA to compare the optic neuritis 
subgroups. pu = percentage units. ns = not significant. 
 
 
  
 Table 3: Periventricular (1-5mm) and deep (6-10mm) MTR gradients in 
normal appearing white matter (NAWM) of people with optic neuritis (ON) and 
healthy controls (HC). 
 
 
Clinical 
classification 
at 2 years 
N 
MTR gradient 
mean ± SE (pu/mm) 
Periventricular 
(1 to 5 mm) 
Deep 
(6 to 10 mm) 
Healthy controls 37 -0.033 ± 0.028 -0.009 ± 0.012 
Optic 
Neuritis 
Did not convert 
to CDMS 
40 0.016 ± 0.029 0.020 ± 0.010 
Converted to 
CDMS 
18 0.132 ± 0.041* -0.010 ± 0.019 
Did not convert 
to McDonald MS 
18 0.015 ± 0.048 0.021 ± 0.015 
Converted to 
McDonald MS 
40 0.069 ± 0.028** 0.006 ± 0.011 
 
Optic neuritis group divided according to conversion to clinically definite 
multiple sclerosis (CDMS) status within two years. *Converters vs. healthy 
controls p=0.001, converters vs. non-converters: p=0.020, non-converters vs. 
healthy controls p=0.221). Optic neuritis group also divided according to 
conversion to McDonald MS within two years. **converters vs healthy controls 
p=0.014; otherwise, no significant differences in gradients detected. 
 
  
Supplementary data 
Supplementary Table 1. Comparison of baseline clinical and radiological 
demographics in those with and without follow up at two and five years. 
 
 
 
 
 
 
 
 
 
 
 People with optic neuritis Significance 
People with 
clinical follow-up 
People without 
clinical follow-up 
 
N N = 58 N = 13  
Mean age, years ± SD (range) 33.5 ± 6.4 (27-48) 33.6 ± 8.1 (21-46) p = 0.966 
female : male  40 : 18 9 : 4 p = 1.000 
Median baseline EDSS (range) 1 (0-3) 1 (0-2) p = 0.585 
Number with abnormal T2 scan 
(excluding symptomatic lesion) 
46 9 p = 0.471 
Number with periventricular lesions 40 6 p = 0.197 
Number with Gd-enhancing lesions 19 3 p = 0.741 
Mean brain parenchymal fraction ± 
SD 
0.85 ± 0.04 0.85 ± 0.03 p = 0.388 
Mean inner MTR gradient ± SE 0.05 ± 0.02 0.09 ± 0.04 p = 0.378 
Comparative results: capability of mean MTR in ring 1 and ring 5 for 
predicting conversion to CDMS and EDSS at 5 years 
 
Conversion to CDMS – ring 1. 
In one-way ANOVA, the mean MTR of ring 1 in the ON group who developed 
CDMS within two years was significantly smaller than in healthy controls, but 
was not significantly different when compared to the ON group who did not 
develop CDMS within two years (converters vs healthy controls p=0.000; 
converters vs non-converters p=0.077; non-converters vs healthy controls 
p=0.007). The results for conversion at five years were broadly similar 
(converters vs healthy controls p=0.000; converters vs non-converters 
p=0.301; non-converters vs healthy controls p=0.014). 
 
Conversion to CDMS – ring 5. 
In one-way ANOVA, the mean MTR of ring 5 in the ON group who developed 
CDMS within two years was not significantly smaller than in healthy controls 
or the ON group who did not develop CDMS within two years (converters vs 
healthy controls p=0.062; converters vs non-converters p=0.893; non-
converters vs healthy controls p=0.012). The results at five years were 
broadly similar (converters vs healthy controls p=0.031; converters vs non-
converters p=0.764; non-converters vs healthy controls p=0.017). 
 
Disability 
We found no correlation between the mean MTR values in rings 1 and 5 with 
EDSS score at five years (p=0.165 and p=0.540 respectively).  
 
 
Effect of conversion to CDMS before MTR scan. 
As a confirmatory analysis we excluded those 8 ON subjects who converted 
to MS in the interval between the baseline clinical MRI and the MTR 
acquisition. Despite the reduced power, the pattern in group differences in 
periventricular MTR gradients was maintained: ON vs healthy controls (0.050 
pu/mm ± 0.022 vs. -0.033 pu/mm ± 0.028, p=0.022); ON converting to CDMS 
within two years vs HC (0.114 pu/mm ±0.051 vs. -0.033 pu/mm ± 0.028, 
p=0.016); ON converting to CDMS within two years vs non-converters (0.114 
pu/mm ±0.051 vs.  0.016 pu/mm ± 0.028, p=0.102). 
 
MTR gradient threshold calculations 
The range of periventricular MTR gradients found in those who developed 
CDMS within 2 years (-0.20 to 0.40 pu/mm) compared to those who did not (-
0.41 to 0.62 pu/mm) - and in those who developed McDonald MS within two 
years (-0.41 to 0.40 pu/mm) compared to those who did not (-0.35 to 0.62 
pu/mm) - overlapped substantially, and there was no clear cut off beyond 
which conversion from a CIS to MS was inevitable. The same pattern was 
seen when examining conversion versus no conversion at 5 years (CDMS: -
0.41 to 0.40 pu/mm; -0.35 to 0.62 pu/mm) (McDonald MS: -0.41 to 0.40 
pu/mm; -0.35 to 0.62 pu/mm).  
 
When we use the mean MTR gradient of the group who did not develop 
CDMS within 2 years as a cut-off (n=40), 13/18 (72%) of those converting to 
CDMS within 2 years had a greater MTR gradient; if a mean + 1 SD threshold 
is used, 7/18 (39%, expected by chance 16%); and greater than the mean + 2 
SD 1/18 (6%, expected by chance 2%). In comparison, the proportion of 
controls exceeding these thresholds were: mean 14/37 (38%); mean + 1 SD 
3/37 (8%); mean + 2 SD 1/37 (3%). When we repeated this using the mean 
MTR gradient of controls as the threshold (n=37), 15/18 (83%) of those 
converting to CDMS within 2 years had a greater MTR gradient compared to 
26/40 (65%) of those not converting within 2 years; if a mean + 1 SD 
threshold was used, respectively 9/18 (50%) and 9/40 (23%) exceeded the 
threshold, and greater than the mean + 2 SD 4/18 (22%) and 1/40 (3%). 
 
  
Figure Legends 
Figure 1. A: Normal appearing white matter (NAWM) from two 5mm axial 
slices were extracted at (B) and immediately below (C) the level of the insula.  
Rings of concentric MTR values from the normal-appearing white matter 
around the ventricles were then extracted (D and E). The first two rings were 
excluded to minimise partial volume effects. 
 
Figure 2A: Normal-appearing white matter (NAWM) MTR of rings in healthy 
controls (HC - blue) and people with optic neuritis 4.6 months after symptom 
onset (ON - red). Mean ± 2 standard error (SE).  MTR is expressed as 
percentage units (pu). Ring 1 is closest to the ventricular surface. 
 
Figure 2B: Normal appearing white matter (NAWM) MTR in healthy controls 
(HC - blue) and people with optic neuritis 4.6 months after symptom onset 
(ON), divided into those with (green) and without (yellow) asymptomatic 
lesions on their baseline scan. Mean ± 2 standard errors (SE) is shown. MTR 
is expressed as percentage units (pu). Ring 1 is closest to the ventricular 
surface. 
 
Figure 2C: Normal appearing white matter (NAWM) MTR in people with optic 
neuritis 4.6 months after symptom onset (ON) plus asymptomatic lesions, 
divided into those with (n=46, green circles) and without (n=9, yellow circles) 
periventricular lesions. Mean ± 2 standard error (SE). MTR is expressed as 
percentage units (pu). Ring 1 is closest to the ventricular surface. 
 
Figure 2D: Normal appearing white matter (NAWM) MTR in healthy controls 
(HC - blue) and people with optic neuritis 4.6 months after symptom onset 
(ON), divided into those who did convert to clinically definite multiple sclerosis 
(CDMS) within two years (gold) and those that did not (green). Mean ± 2 
standard errors (SE) is shown. MTR is expressed as percentage units (pu). 
Ring 1 is closest to the ventricular surface. 
 
 
Figure 3: Mean MTR of white matter (WM) lesional voxels in patients with 
optic neuritis 4.6 months after symptom onset (ON). Mean ± 2 standard error 
(SE). MTR is expressed as percentage units (pu). Ring 1 is closest to the 
ventricular surface. 
 
Figure 4: Percentage of lesional white matter (WM) per ring in patients with 
optic neuritis 4.6 months after symptom onset (ON). Mean ± 2 standard error 
(SE). Ring 1 is closest to the ventricular surface. 
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